These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019. Karlowsky JA; Kazmierczak KM; Valente MLNF; Luengas EL; Baudrit M; Quintana A; Irani P; Stone GG; Sahm DF Braz J Infect Dis; 2021; 25(6):101647. PubMed ID: 34774471 [TBL] [Abstract][Full Text] [Related]
4. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018). Piérard D; Stone GG BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15. Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF J Antimicrob Chemother; 2018 Oct; 73(10):2782-2788. PubMed ID: 30010894 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15. Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF J Antimicrob Chemother; 2018 Oct; 73(10):2777-2781. PubMed ID: 30010951 [TBL] [Abstract][Full Text] [Related]
8. Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016. Sader HS; Castanheira M; Shortridge D; Mendes RE; Flamm RK Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827415 [TBL] [Abstract][Full Text] [Related]
9. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017). Ko WC; Stone GG Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155 [TBL] [Abstract][Full Text] [Related]
10. In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014). de Jonge BL; Karlowsky JA; Kazmierczak KM; Biedenbach DJ; Sahm DF; Nichols WW Antimicrob Agents Chemother; 2016 May; 60(5):3163-9. PubMed ID: 26926648 [TBL] [Abstract][Full Text] [Related]
11. Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015). Sader HS; Huband MD; Duncan LR; Flamm RK Pediatr Infect Dis J; 2018 Jun; 37(6):549-554. PubMed ID: 29206750 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014-2017 and 2018. Kristóf K; Adámková V; Adler A; Gospodarek-Komkowska E; Rafila A; Billová S; Możejko-Pastewka B; Kiss F Diagn Microbiol Infect Dis; 2021 Sep; 101(1):115420. PubMed ID: 34091111 [TBL] [Abstract][Full Text] [Related]
13. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015. Sader HS; Castanheira M; Flamm RK Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015-2017. Stone GG; Seifert H; Nord CE Int J Antimicrob Agents; 2020 Sep; 56(3):106045. PubMed ID: 32522673 [TBL] [Abstract][Full Text] [Related]
15. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme. Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399 [TBL] [Abstract][Full Text] [Related]
16. ARGONAUT-III and -V: susceptibility of carbapenem-resistant Jacobs MR; Abdelhamed AM; Good CE; Mack AR; Bethel CR; Marshall S; Hujer AM; Hujer KM; Patel R; van Duin D; Fowler VG; Rhoads DD; Six DA; Moeck G; Uehara T; Papp-Wallace KM; Bonomo RA Antimicrob Agents Chemother; 2024 Sep; 68(9):e0075124. PubMed ID: 39133021 [TBL] [Abstract][Full Text] [Related]
17. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States. Sader HS; Huband MD; Castanheira M; Flamm RK Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652 [No Abstract] [Full Text] [Related]
18. Longitudinal analysis of the in vitro activity of ceftazidime/avibactam versus Enterobacteriaceae, 2012-2016. Ramalheira E; Stone GG J Glob Antimicrob Resist; 2019 Dec; 19():106-115. PubMed ID: 31295583 [TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ceftazidime/avibactam and comparators against Gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017. Stone GG; Ponce-de-Leon A J Antimicrob Chemother; 2020 Jul; 75(7):1859-1873. PubMed ID: 32277820 [TBL] [Abstract][Full Text] [Related]
20. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the Yin D; Wu S; Yang Y; Shi Q; Dong D; Zhu D; Hu F; Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30617091 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]